Delta Apparelの空売り状況は、投資家がDelta Apparelの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Delta Apparel (OTC:DLAPQ) 株価情報, 空売り情報

Delta Apparel Inc together with its subsidiaries is an international apparel design, marketing, manufacturing, and sourcing company. It operates its business in two distinct segments: Delta Group and Salt Life Group. The company offers a diverse portfolio of lifestyle basics and branded activewear apparel, headwear, and related accessory products. It specializes in selling casual and athletic products through distribution channels and distribution tiers, including specialty stores, boutiques, department stores, mid and mass channels, e-retailers, and the U.S. military. It also offers its products to consumers on its websites and in its retail stores. The company derives the maximum revenue from the wholesale of goods through the Delta Group in the United States.

DELTA APPAREL INC by Delta Apparel Company

Delta Apparel Inc

TD Securities analyst Andrew Charles reiterates Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Buy and maintains $105 price target.

News

Price Target

Reiteration

Analyst Ratings

SHAK

TD Securities Reiterates Buy on Shake Shack, Maintains $105 Price Target

First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies
Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies
SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), and Ovation.io, Inc.,&nbsp;an organization dedicated to building best-in-class multiomics datasets, today announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. This collaboration is the latest in a series of efforts to partner across the ecosystem, and deploy multimodal data to advance a deeper understanding of biology.
One in eight adults in the United States have used a GLP-1 receptor agonist, according to a 2024 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417889-1&amp;h=3609831402&amp;u=https%3A%2F%2Fwww.kff.org%2Fhealth-costs%2Fpoll-finding%2Fkff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs%2F&amp;a=health+tracking+poll">health tracking poll</a> conducted by the Kaiser Family Foundation. However, roughly 40% of users with Type 2 diabetes do not respond effectively to GLP-1 receptor agonists, according to a study <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417889-1&amp;h=668246930&amp;u=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fabs%2Fpii%2FS1871402124001474%3FviewFullText%3Dtrue&amp;a=published+in+Diabetes+%26+Metabolic+Syndrome">published in Diabetes &amp; Metabolic Syndrome</a> in 2024. The collaboration aims to accelerate GLP-1 therapy development, indication expansion research, and discovery of novel biomarkers and drug targets in nonresponsive populations.

Biotech

General

ILMN

Illumina And Ovation.io Launching GLP-1 Dataset To Accelerate New Therapy Development

UBS analyst Joseph Spak maintains Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) with a Buy and raises the price target from $18 to $20.

UBS Maintains Buy on Dana, Raises Price Target to $20

Evercore ISI Group analyst David Motemaden maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a In-Line and lowers the price target from $400 to $396.

Evercore ISI Group Maintains In-Line on Everest Group, Lowers Price Target to $396

Intuitive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP's capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorectal excision, colectomy, abdominoperineal resection, and sigmoidectomy.
Intuitive engineered the da Vinci SP system to navigate in narrow body cavities requiring precise access, such as lower pelvis and rectal procedures. Its design and architecture support access to rectal anatomy by allowing surgeons to control up to three multi-jointed instruments and a high-definition articulating camera through a single entry point to work freely in the smaller space.
Da Vinci SP also helps mitigate challenges inherent with laparoscopic transanal minimally invasive surgery, such as surgeon ergonomics, reaching lesions in the upper rectum, and working circumferentially, or "upside-down," when needed.

ISRG

Intuitive Announces The U.S. FDA Cleared The Da Vinci Single Port Surgical System For Transanal Local Excision/Resection

<ul>
<li>TSLA</li>
<li>AAPL</li>
<li>MSFT</li>
<li>AMZN</li>
<li>NVDA</li>
<li>META</li>
<li>MCD</li>
<li>BULL</li>
<li>PLTR</li>
<li>GLD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

AMZN

BULL

MSFT

NVDA

PLTR

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 1, 2025 (Via Swaggy Stocks)

UBS analyst Mark Carden maintains The Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $67 to $68.

CHEF

UBS Maintains Buy on The Chefs' Warehouse, Raises Price Target to $68

Evercore ISI Group analyst Mark Mahaney maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a In-Line and raises the price target from $63 to $69.

EBAY

Evercore ISI Group Maintains In-Line on eBay, Raises Price Target to $69

SRx Health Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRXH#NYSE">SRXH</a>) (the "Company"), a leading global health and wellness company, today announced that it will explore an initiative to allocate up to 10% of future cash flows and cash reserves into cryptocurrencies and precious metals, including Bitcoin (BTC), Solana (SOL), as well as physical gold and silver.

SRXH

SRx Health Solutions To Explore Initiative To Allocate Up To 10% Of Future Cash Flows And Cash Reserves Into Cryptocurrencies And Precious Metals

UBS analyst Dan Leonard upgrades Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) from Neutral to Buy and lowers the price target from $145 to $115.

Upgrades

RVTY

UBS Upgrades Revvity to Buy, Lowers Price Target to $115

Evercore ISI Group analyst Jonathan Chappell maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Outperform and lowers the price target from $89 to $88.

Evercore ISI Group Maintains Outperform on Canadian Pacific Kansas, Lowers Price Target to $88

Politics

Global

During Conference Call, GM CFO Reportedly Says $4B-$5B Is Our Estimated Impact After President's Actions For 2025, It Does Not Include 30% Offsets

Company Provides Preliminary Expectations for First Quarter 2025 Financial Results
In connection with today's announcement, Kohl's is providing preliminary expectations for its financial results for the first quarter of 2025:
For the first quarter 2025, the Company currently expects the following:
<ul>
<li>Comparable sales: In the range of (4.3%) to (4.0%)</li>
<li>Operating income: In the range of $40 million to $45 million</li>
<li>Diluted EPS: In the range of ($0.24) to ($0.20)</li>
</ul>

Guidance

Kohl's Now Expects Q1 EPS Of ($0.24) to ($0.20); Sees Operating Income Of $40M - $45M

Evercore ISI Group analyst Robert Ottenstein maintains Vita Coco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCO#NASDAQ">COCO</a>) with a Outperform and raises the price target from $35 to $38.

COCO

Evercore ISI Group Maintains Outperform on Vita Coco, Raises Price Target to $38

Stephens &amp; Co. analyst Jim Salera maintains Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) with a Equal-Weight and lowers the price target from $200 to $195.

LANC

Stephens & Co. Maintains Equal-Weight on Lancaster Colony, Lowers Price Target to $195

Crude oil's decline shows no signs of ending, with prices sinking more than 2% below $57 per barrel on Thursday morning as markets brace for a potential OPEC+ supply hike and rising signs of economic <a href="https://www.benzinga.com/news/econ-s">stress across major economies.</a>
West Texas Intermediate crude futures – as closely represented by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) – are now on track to log four straight days of declines and reach April lows, when front-month contracts broke below $55, marking the cheapest level in over four years.
Since peaking in March 2022, oil prices have plunged 55%, with a 21% drop year-to-date and a 30% decline over the past 12 months, indicating a persistent bear market struggling to find a floor.
<h3 class="wp-block-heading">OPEC+ May Raise Supply Despite Falling Prices</h3>
Fresh pressure on prices came from reports that Saudi Arabia has told allies and industry participants it is prepared to endure a longer stretch of low prices without further supply cuts. 
This strengthened speculation that OPEC+ could unveil a new production increase at its May 5 meeting.
David Goldman, head of trading at Novion Global, said reports about Riyadh&#8217;s stance triggered Thursday's sharp sell-off. 
"Oil prices fell as much as 4% after reports that Saudi Arabia can endure a sustained period of depressed prices," he said, noting that the market fears a longer period of surplus supply from the Saudi-led alliance.
Goldman Sachs analyst Daan Struyven expects OPEC+ to raise production modestly by 100,000 barrels per day in June and July, keeping output steady afterward. Yet, the risks are tilted toward a more aggressive ramp-up. "Kazakhstan&#8217;s focus on national interests increases risks of a larger OPEC+ production hike in June," Struyven said.
&#8220;While the 90-day pause on reciprocal tariffs provided a stay of execution, the chances of recession remains unusually high,&#8221; he added. 
Adding to bearish sentiment was the latest GDP report, which showed the U.S. economy contracted in the first quarter for the first time in three years.
Goldman Sachs' economics team now sees a 45% probability of a U.S. recession in the next 12 months, citing persistently high policy uncertainty, weak real income growth and cautious consumer spending. 
They believe oil prices could fall even more during a recession than during a typical growth slowdown.
&#8220;Oil prices are likely to decline more in the next recession relative to the slowdown in global growth and in oil demand because OPEC supply is likely to fall less than the median-peak-to-trough decline of 2.7mb/d in for the last three recessions,&#8221; Struyven said.
<h3 class="wp-block-heading">&#8216;The Cure For Low Oil Prices Is Low Oil Prices&#8217;</h3>
David Morrison, senior market analyst at Trade Nation, said the bearish backdrop is reinforced by structural demand weakness in China and new geopolitical risks. 
"The global demand growth outlook was weak even before President Trump began his trade war," he said. "Now it has to deal with Trump's tariffs which have effectively ended trade between the U.S. and China."
&#8220;OPEC+ is in no mood to step in to support the&nbsp;oil&nbsp;price. Quite the contrary, as the group is anxious to unwind the production cuts which did so much to support the&nbsp;oil&nbsp;price over the past couple of year,&#8221; he added.
Still, he indicated that markets rarely move in straight lines. Sharp bottoms, like sharp tops, often signal a turning point, though it&#8217;s too early to say whether crude has reached that stage. 
Amid mixed signals and rising uncertainty, Morrison suggested that oil remains tough to trade, but reiterated a familiar market truism: "The cure for low oil prices is low oil prices."
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45115660/3-stocks-to-turn-tariffs-into-opportunities">3 Stocks To Turn Tariffs Into Opportunities</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Macro Economic Events

Commodities

Econ #s

Economics

Oil Sinks Below $57 On OPEC+ Supply Speculation, Bear Market Deepens

Evercore ISI Group analyst Jonathan Chappell maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Outperform and lowers the price target from $119 to $110.

CHRW

Evercore ISI Group Maintains Outperform on C.H. Robinson Worldwide, Lowers Price Target to $110

Kohl's Expects Q1 Comp Sales In The Range Of (4.3%) To (4.0%)

Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) reported quarterly earnings of $2.30 per share which beat the analyst consensus estimate of $2.17 by 5.99 percent. This is a 6.98 percent increase over earnings of $2.15 per share from the same period last year. The company reported quarterly sales of $540.23 million which missed the analyst consensus estimate of $541.53 million by 0.24 percent. This is a 7.74 percent increase over sales of $501.43 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cullen/Frost Bankers Q1 EPS $2.30 Beats $2.17 Estimate, Sales $540.23M Miss $541.53M Estimate

Jefferies analyst Omar Nokta maintains Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) with a Buy and maintains $65 price target.

Comments

Delta Apparel

空売り

Delta Apparel (OTC:DLAPQ) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル